Navigation Links
BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010
Date:5/6/2010

approval; BYETTA and/or the approval of BYDUREON and the revenues generated from these products may be affected by competition; unexpected new data; safety and technical issues; clinical trials not being completed in a timely manner, not confirming previous results, not being predictive of real world use or not achieving the intended clinical endpoints; label expansion requests or NDA filings, such as the NDA filing for BYDUREON mentioned in this press release, not receiving regulatory approval; the commercial launch of BYDUREON being delayed; or manufacturing and supply issues. The potential for BYETTA and/or BYDUREON may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products including those inherent in the collaboration with and dependence upon Amylin, Lilly and/or Alkermes. These and additional risks and uncertainties are described more fully in Amylin's, Lilly's and Alkermes' most recent SEC filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin, Lilly and Alkermes undertake no duty to update these forward-looking statements.

BYDUREON™ and BYETTA® are trademarks of Amylin Pharmaceuticals, Inc., and Medisorb® is a registered trademark of Alkermes, Inc. 

P-LLY

(i) The International Diabetes Federation Diabetes Atlas. Available at: http://www.diabetesatlas.org/content/some-285-million-peopl
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
5. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
6. AEterna Zentaris Announces Outcome of Managements Strategic Review
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 Polaris Group announced today ... its Phase 1 trial of ADI-PEG 20 in ... of malignant pleural mesothelioma (MPM) and non-squamous non-small ... trials on ADI-PEG 20, both as monotherapy and ... of several other indications, including breast cancer, melanomas, ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood Registry® ... of the 10th Annual World Stem Cell Summit, the largest ... The 2014 World Stem Cell Summit will be held December ... Texas . The World Stem ... of lifesaving cures and therapies, convening the most prominent figures ...
(Date:11/18/2014)... 17, 2014 Athena Signature Series: Turning Cancer ... Beverly Emerson, a professor in the Regulatory Biology Laboratory at ... recent discovery points to an “off switch” for drug resistance ... how her local research is making a global impact in ... and then join host Cheryl K. Goodman, CEO of Social ...
(Date:11/18/2014)... Texas (PRWEB) November 18, 2014 ... Polytetrahydrofuran (PTMEG) Industry is professional and in-depth ... gives Polytetrahydrofuran basic information, including its definition, ... also industry outline. This exploration covers the ... and worldwide industry examination covering macroeconomic environment ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... 21 Richter-Helm,BioLogics GmbH & Co. KG and ... development and manufacturing of Athera,s novel product for,prevention ... the,protein, Annexin A5, to endothelium. The recombinant protein ... with Acute Coronary Syndrome and who,are at imminent ...
... YORK, Jan. 20 Immtech Pharmaceuticals, Inc. (NYSE ... has appointed Virchow, Krause & Company, LLP as ... The decision to change the Company,s independent registered ... board of directors. The appointment will result ...
... - Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) today ... on January 13, 2009, indicating that it no longer ... in Nasdaq Marketplace Rule 4350(c)(1) (the "Rule"). The letter ... which was announced publicly in a January 6, 2009 ...
Cached Biology Technology:Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease 2Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease 3Immtech Announces Appointment of Virchow Krause as Independent Registered Public Accounting Firm 2Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1) 2
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... study published in this month,s Proceedings of ... of a recently discovered communication molecule of the body,s ... known to limit inflammation and the current study reports ... the ability of the immune system to recognize and ... IL-37,s effect on the immune system now allows us ...
(Date:11/2/2014)... 2014)—In support of a bold quest to rid the ... Foundation today announced an award of US$156 million to ... in building new vaccines that will interrupt the cycle ... to zero" agenda. Such vaccines would ensure that parasite ... an "immunological bed net." , This approach to ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4
... (Dec. 5, 2013) A new method to identify ... speed the process of novel drug design, according to ... computational techniques and experimental data helped Rice theorists predict ... hard to detect. The work should be ...
... on a shark" is the take home message from an ... Ritter of the Shark Research Institute and Raid Amin of ... sharks can comprehend body orientation and therefore know whether humans ... approach and possibly attack their prey from the blind side ...
... effectively implement the well-known double-stranded structure and the elasticity ... by Jae-Hyung Jeon and Wokyung Sung of Pohang University ... in an effort to more comprehensively explore the nucleic ... published in Springer,s Journal of Biological Physics . ...
Cached Biology News:Proteins' passing phases revealed 2Proteins' passing phases revealed 3Sharks prefer to sneak up from behind, study shows 2DNA helicity and elasticity explained on the nanoscale 2
Dedicated 29.5" X 18" platforms for Stackable shakers. These platforms are optimized for a particular flask clip size and are sold with a full load of flask clips....
... Reverse Transcriptase (RT) is an improved version ... is a DNA polymerase that synthesizes a ... or an RNA:DNA hybrid. This enzyme is ... mutations rather than a deletion in the ...
... SuperScript™ II RNase H- Reverse Transcriptase (RT) ... RNase H- RT. It is a DNA ... from single-stranded RNA DNA or an RNA:DNA ... the introduction of point mutations rather than ...
... (PNK) catalyzes the transfer of the ... of single- and double-stranded DNA, RNA, ... removes the 3'-phosphate from 3'-phosphoryl polynucleotides, ... to form a 3'-hydroxyl group. Storage ...
Biology Products: